The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss |
|
Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease. |
|
Chefen sagde: "Find lige på noget nyt" |
|
Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats |
|
Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats. |
|
Comment on Andersen et al, pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop |
|
Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125. |
|
Development of a cysteine-deprived and C-terminally truncated GLP-1 receptor. |
|
Drug discovery and development of agonists for the glucagon-like peptide-1 receptor |
|
The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. |
|
Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. |
|
Expression of the GLP-1 receptor in mouse, rat, and human pancreas |
|
Functional importance of GLP-1 receptor species and expression levels in cell lines. |
|
A genetic map of the mouse dorsal vagal complex and its role in obesity |
|
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways. |
|
GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress |
|
GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics |
|
GLP-1 Induces Barrier Protective Expression in Brunner's Glands and Regulates Colonic Inflammation. |
|
The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy. |
|
GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. |
|
GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. |
|
GLP-1 regulates the POMC neurons of the arcuate nucleus both directly and indirectly via presynaptic action |
|
Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor |
|
The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates. |
|
Human glucagon receptor antagonists with thiazole cores. A novel series with superior pharmacokinetic properties. |
|
Integrated Brain Atlas for Unbiased Mapping of Nervous System Effects Following Liraglutide Treatment |
|
Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling |
|
Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. |
|
Liraglutide: the therapeutic promise from animal models. |
|
Lixisenatide in the treatment of Type 2 diabetes |
|
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice |
|
The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro |
|
Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus |
|
Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome. |
|
Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease |
|
New beta-alanine derivatives are orally available glucagon receptor antagonists |
|
NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs |
|
Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor. |
|
The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance. |
|
Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. |
|
Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide. |
|
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration |
|
Quantitative whole-brain 3D imaging of tyrosine hydroxylase-labeled neuron architecture in the mouse MPTP model of Parkinson's disease |
|
Semaglutide lowers body weight in rodents via distributed neural pathways |
|
Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor |
|
Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness |
|
Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. |
|
Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus |
|
Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist |
|
Transmembrane α-Helix 2 and 7 Are Important for Small Molecule-Mediated Activation of the GLP-1 Receptor |
|
The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist |
|